Latest news with #TScanTherapeutics
Yahoo
28-05-2025
- Business
- Yahoo
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time. A webcast of the presentation will be available on the 'Events and Presentations' section of the Company's website at An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs. Contacts Heather SavelleTScan Therapeutics, Investor Relations857-399-9840hsavelle@ Maghan MeyersArgot Partners212-600-1902TScan@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
25-05-2025
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report), Beam Therapeutics (BEAM – Research Report) and TScan Therapeutics (TCRX – Research Report). Confident Investing Starts Here: Novo Nordisk (NVO) In a report issued on May 6, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with a price target of $64.00. The company's shares closed last Friday at $67.35. According to Seigerman is a 4-star analyst with an average return of 3.2% and a 42.7% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Protagonist Therapeutics, and Arvinas Holding Company. The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a $92.44 average price target. BMO Capital analyst Kostas Biliouris maintained a Buy rating on Beam Therapeutics on May 7 and set a price target of $40.00. The company's shares closed last Friday at $16.83. According to Biliouris has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.1% and a 29.2% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Rocket Pharmaceuticals. Beam Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.13, implying a 164.3% upside from current levels. In a report issued on May 6, William Blair also maintained a Buy rating on the stock. TScan Therapeutics (TCRX) BTIG analyst Jeet Mukherjee maintained a Buy rating on TScan Therapeutics on May 21 and set a price target of $12.00. The company's shares closed last Friday at $1.38, close to its 52-week low of $1.34. According to Mukherjee has 0 stars on 0-5 stars ranking scale with an average return of -15.8% and a 31.6% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Janux Therapeutics Inc, and Carisma Therapeutics. Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $9.33, representing a 557.0% upside. In a report issued on May 6, TD Cowen also maintained a Buy rating on the stock.
Yahoo
27-02-2025
- Business
- Yahoo
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. A webcast of the presentation will be available on the 'Events and Presentations' section of the Company's website at An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs. Contacts Heather SavelleTScan Therapeutics, Investor Relations857-399-9840hsavelle@ Maghan MeyersArgot Partners212-600-1902TScan@ in to access your portfolio
Yahoo
18-02-2025
- Business
- Yahoo
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time. A webcast of the fireside chat will be available on the 'Events and Presentations' section of the Company's website at An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-TTM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs. Contacts Heather SavelleTScan Therapeutics, Investor Relations857-399-9840hsavelle@ Maghan MeyersArgot Partners212-600-1902TScan@ in to access your portfolio
